Kester Capital-backed Evestia Clinical merges with US-based Atlantic Research Group (ARG) to create a leading independent global specialist CRO in fast-growing marketsThe merger delivers on Evestia ...

University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.

A recent phase 2b clinical trial in South Africa found that Bacille Calmette-Guérin (BCG) revaccination did not prevent ...

In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by ...

STOCKHOLM, SE / ACCESS Newswire / July 15, 2025 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

Dr. Vincent Ma discussed the most recent and notable treatment updates for patients with high-risk and advanced melanoma.

Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technologyPrecli ...

Researchers at the La Jolla-based Salk Institute for Biological Studies say they recently identified a brain circuit that ...